Boston Scientific Begins Clinical Trial For Next-Generation Nitinol Stent To Treat Iliac Artery Disease
Boston Scientific Corporation (NYSE: BSX) announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company"s EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that impacts a patient"s lower extremities. The first U.S. patient was enrolled on May 14 by Nicolas W. Shammas, M.D., at Trinity Terrace Park Hospital in Bettendorf, Iowa.
Public Health
Pages: 1 [2]
Better Monitoring, Better Prognosis In Liver Disease
to limit their carbohydrate intake in order to prevent prediabets and diabetes. The study subjects were all from Brooklyn, New York, and Dr. Anand said investigators may consider a follow-up study that surveys a larger group throughout the country. His group intends to survey primary physicians" and residents" awareness about NAFLD. Dr. Nan Sandar will present these data on Tuesday, June 2 at 8 a.m. CDT in South Hall, McCormick Place. Aimee Frank American Gastroenterological AssociationPages: 1 [2]